133 related articles for article (PubMed ID: 35254504)
1. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
Ikesue H; Yamaoka K; Matsumoto A; Hirabatake M; Muroi N; Yamasaki T; Kawakita M; Hashida T
Cancer Chemother Pharmacol; 2022 Jun; 89(6):833-838. PubMed ID: 35254504
[TBL] [Abstract][Full Text] [Related]
2. Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
Nihei S; Sato J; Harada T; Kuyama S; Suzuki T; Waga N; Saito Y; Kisara S; Yokota A; Okada K; Tsuchiya M; Terui K; Tadokoro Y; Chiba T; Kudo K; Oizumi S; Inoue A; Morikawa N
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1051-1059. PubMed ID: 29651572
[TBL] [Abstract][Full Text] [Related]
3. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
4. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.
Miyake H; Harada K; Imai S; Miyazaki A; Fujisawa M
Int J Clin Oncol; 2015 Aug; 20(4):796-801. PubMed ID: 25424248
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
6. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
7. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.
Mishima E; Haruna Y; Arima H
Hypertens Res; 2019 Apr; 42(4):469-482. PubMed ID: 30948820
[TBL] [Abstract][Full Text] [Related]
9. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.
Numakura K; Igarashi R; Takahashi M; Nara T; Kanda S; Saito M; Narita S; Inoue T; Niioka T; Miura M; Habuchi T
Cancer Biol Ther; 2024 Dec; 25(1):2312602. PubMed ID: 38327067
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
11. Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study.
Uchida M; Kawazoe H; Takatori S; Namba H; Uozumi R; Tanaka A; Kawasaki H; Araki H
Clin Ther; 2018 Jul; 40(7):1214-1222.e1. PubMed ID: 29983264
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system inhibitors for countering proteinuria induced by angiogenesis inhibitors: a retrospective observational analysis.
Hirai T; Shuji Y; Takiyama M; Hanada K; Itoh T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):195-202. PubMed ID: 31119376
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of Renin-Angiotensin System Blockade on Renal Cell Carcinoma After Surgery.
Miyajima A; Yazawa S; Kosaka T; Tanaka N; Shirotake S; Mizuno R; Kikuchi E; Oya M
Ann Surg Oncol; 2015 Oct; 22(11):3751-9. PubMed ID: 25691280
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Proteinuria Using Urine Protein : Creatine Ratio in Treatment with Molecular Targeted Agents for Advanced Renal Cell Carcinoma.
Nakamura K; Tanaka T; Masumori N; Miyamoto A; Hirano T
Biol Pharm Bull; 2020; 43(10):1506-1510. PubMed ID: 32999160
[TBL] [Abstract][Full Text] [Related]
15. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
16. [Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients].
Kusakabe N; Osawa T; Miyata H; Kikuchi H; Matsumoto R; Maruyama S; Abe T; Shinohara N
Hinyokika Kiyo; 2018 Sep; 64(9):353-358. PubMed ID: 30369225
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy.
Yoshida K; Takagi T; Kondo T; Kobayashi H; Iizuka J; Fukuda H; Ishihara H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2019 Jun; 49(6):576-580. PubMed ID: 30924496
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
[TBL] [Abstract][Full Text] [Related]
19. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study.
Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W
Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528
[TBL] [Abstract][Full Text] [Related]
20. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
